These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26879594)

  • 1. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer.
    Gupta A; Jarzab B; Capdevila J; Shumaker R; Hussein Z
    Br J Clin Pharmacol; 2016 Jun; 81(6):1124-33. PubMed ID: 26879594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
    Tamai T; Hayato S; Hojo S; Suzuki T; Okusaka T; Ikeda K; Kumada H
    J Clin Pharmacol; 2017 Sep; 57(9):1138-1147. PubMed ID: 28561918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer.
    Hayato S; Shumaker R; Ferry J; Binder T; Dutcus CE; Hussein Z
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):971-978. PubMed ID: 30244318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients.
    Salem AH; Koenig D; Carlson D
    Clin Pharmacokinet; 2014 Apr; 53(4):347-59. PubMed ID: 24307488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration.
    Shumaker R; Aluri J; Fan J; Martinez G; Pentikis H; Ren M
    J Clin Pharmacol; 2015 Mar; 55(3):317-27. PubMed ID: 25204557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
    Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
    Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
    Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
    Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
    Patel P; Howgate E; Martin P; Carlile DJ; Aarons L; Zhou D
    Br J Clin Pharmacol; 2018 Jan; 84(1):52-63. PubMed ID: 28833380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
    Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
    Hewett Y; Ghimire S; Farooqi B; Shah BK
    J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.
    Hussein Z; Mizuo H; Hayato S; Namiki M; Shumaker R
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):903-914. PubMed ID: 28236116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)
    Gaspar N; Campbell-Hewson Q; Gallego Melcon S; Locatelli F; Venkatramani R; Hecker-Nolting S; Gambart M; Bautista F; Thebaud E; Aerts I; Morland B; Rossig C; Canete Nieto A; Longhi A; Lervat C; Entz-Werle N; Strauss SJ; Marec-Berard P; Okpara CE; He C; Dutta L; Casanova M
    ESMO Open; 2021 Oct; 6(5):100250. PubMed ID: 34562750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
    Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
    Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
    Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
    Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
    Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
    J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?
    Lorusso L; Newbold K
    Future Oncol; 2015; 11(12):1719-27. PubMed ID: 26075440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.